# CanStem111P (NCT02993731)

> A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

No report yet. It can be ordered.

- Drugs tested: napabucasin
- Indication: previously untreated metastatic pancreatic adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02993731
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Sumitomo Pharma America, Inc.
- Conditions: Carcinoma, Pancreatic Ductal
- Interventions: Napabucasin; Nab-paclitaxel; Gemcitabine
- Enrollment: 1134
- Primary outcome: Overall Survival

## Indexed commentary on CanStem111P so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=canstem111p-nct02993731